Molecular targets of the nitrogen containing bisphosphonates: The molecular pharmacology of prenyl synthase inhibition

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 2961-2969

  Dunford, J E ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bisphosphonate; Farnesyl pyrophosphate synthase; Osteoporosis; Prenylation

Indexed keywords

1 DEOXYYLULOSE 5 PHOSPHATE REDUCTOISOMERASE; ALENDRONIC ACID; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; FARNESYL DIPHOSPHATE; GAP JUNCTION PROTEIN; GERANYLGERANYL PYROPHOSPHATE; GLUTAMINE; GLYCINE; GUANOSINE TRIPHOSPHATASE; HEXOKINASE; IBANDRONIC ACID; KETOL ACID REDUCTOISOMERASE; MATRIX METALLOPROTEINASE; MEVALONIC ACID; NE 10790; NE 58022; NE 58043; NE 58051; NITROGEN DERIVATIVE; PAMIDRONIC ACID; PHOSPHATASE; PHOSPHOGLYCERATE KINASE; PRENYL SYNTHASE; PROTEIN TYROSINE PHOSPHATASE; RISEDRONIC ACID; SYNTHETASE; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE METABOLISM; CELL FUNCTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; LIPID MEMBRANE; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; CATALYTIC DOMAIN; DIMETHYLALLYLTRANSTRANSFERASE; DIPHOSPHONATES; DRUG DESIGN; ENZYME INHIBITORS; GERANYLTRANSTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; NITROGEN; OSTEOPOROSIS; PROTEIN PRENYLATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649813078     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563617     Document Type: Article

References (97)

1. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 2003; 12 (Suppl 2): S142-S146.
2. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372: 155-163.
3. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008; 34 (Suppl 1): S19-S24.
4. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117: 209-257.
5. Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P. Bisphosphonates in cancer therapy. Cancer Lett 2007; 257: 16-35.
6. Smith R, Russell RG, Bishop M. Diphosphonates and Page's disease of bone. Lancet 1971; 1: 945-947.
7. Russell RG, Smith R, Bishop MC, Price DA. Treatment of myositis ossificans progressiva with a diphosphonate. Lancet 1972; 1: 10-11.
8. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296: 235-242.
9. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264: 108-111.
10. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999; 255: 491-494.
11. Grove JE, Brown RJ, Watts DJ. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J Bone Miner Res 2000; 15: 971-981.
12. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131-140.
13. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001; 44: 2201-2210.
14. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-2978.
15. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
16. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19: 733-759.
17. Skorey K, Ly HD, Kelly J, et al. How does alendronate inhibit protein-tyrosine phosphatases? J Biol Chem 1997; 272: 22472-22480.
18. Endo N, Rutledge SJ, Opas EE, et al. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 1996; 11: 535-543.
19. Plotkin LI, Lezcano V, Thostenson J, et al. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008; 23: 1712-1721.
20. Heikkila P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13: 245-254.
21. Asante-Appiah E, Patel S, Dufresne C, et al. The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 2002; 41: 9043-9051.
22. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999; 878: 453-465.
23. Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-1374.
24. Cromartie TH, Fisher KJ, Grossman JN. The discovery of a novel site of action for herbicidal bisphosphonates. Pesticide Biochem Physiol 1999; 63: 114-126.
25. Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15: 1467-1476.
26. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998; 13: 1668-1678.
27. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96: 133-138.
28. van Beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14: 722-729.
29. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000; 373: 231-241.
30. Dunford JE, Kwaasi AA, Rogers MJ, et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008; 51: 2187-2195.
31. Amin D, Cornell SA, Gustafson SK, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992; 33: 1657-1663.
32. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-Hydroxy-3- (methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung 1996; 46: 759-762.
33. Bivi N, Romanello M, Harrison R, et al. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome Biol 2009; 10: R93.
34. van Beek ER, Cohen LH, Leroy IM, et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003; 33: 805-811.
35. Thompson K, Dunford JE, Ebetino FH, Rogers MJ. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 2002; 290: 869-873.
36. Wang KC, Ohnuma S. Isoprenyl diphosphate synthases. Biochim Biophys Acta 2000; 1529: 33-48.
37. Cane DE, Abell C, Harrison PH, et al. Terpenoid biosynthesis and the stereochemistry of enzyme-catalysed allylic additionelimination reactions. Philos Trans R Soc Lond B Biol Sci 1991; 332: 123-129.
38. Wang K, Ohnuma S. Chain-length determination mechanism of isoprenyl diphosphate synthases and implications for molecular evolution. Trends Biochem Sci 1999; 24: 445-451.
39. Leung KF, Baron R, Seabra MC. Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res 2006; 47: 467-475.
40. Magee T, Seabra MC. Fatty acylation and prenylation of proteins: what's hot in fat. Curr Opin Cell Biol 2005; 17: 190-196.
41. Tarshis LC, Yan M, Poulter CD, Sacchettini JC. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. Biochemistry 1994; 33: 10871-10877.
42. Tarshis LC, Proteau PJ, Kellogg BA, Sacchettini JC, Poulter CD. Regulation of product chain length by isoprenyl diphosphate synthases. Proc Natl Acad Sci USA 1996; 93: 15018-15023.
43. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103: 7829-7834.
44. Hosfield DJ, Zhang Y, Dougan DR, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004; 279: 8526-8529.
45. Rondeau JM, Bitsch F, Bourgier E, et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 2006; 1: 267-273.
46. Poulter CD, Rilling HC. Prenyltransferase: the mechanism of the reaction. Biochemistry 1976; 15: 1079-1083.
47. Poulter CD, Argyle JC, Mash EA. Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1'-4 coupling reaction with 2-fluorogeranyl pyrophosphate. J Biol Chem 1978; 253: 7227-7233.
48. Poulter CD, Argyle JC, Mash EA. Letter: Prenyltransferase. New evidence for an ionization-condensation-elimination mechanism with 2-fluorogeranyl pyrophosphate. J Am Chem Soc 1977; 99: 957-959.
49. Kavanagh KL, Dunford JE, Bunkoczi G, Russell RG, Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 2006; 281: 22004-22012.
50. Ohnuma S, Hirooka K, Ohto C, Nishino T. Conversion from archaeal geranylgeranyl diphosphate synthase to farnesyl diphosphate synthase. Two amino acids before the first aspartaterich motif solely determine eukaryotic farnesyl diphosphate synthase activity. J Biol Chem 1997; 272: 5192-5198.
51. Williams JW, Morrison JF. The kinetics of reversible tight-binding inhibition. Methods Enzymol 1979; 63: 437-467.
52. Morrison JF. Kinetics of the reversible inhibition of enzymecatalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 1969; 185: 269-286.
53. Yamamoto Y, Kurata M, Watabe S, Murakami R, Takahashi SY. Novel cysteine proteinase inhibitors homologous to the proregions of cysteine proteinases. Curr Protein Pept Sci 2002; 3: 231-238.
54. Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanismbased inhibitors for matrix metalloproteinases. J Biol Chem 2005; 280: 33992-34002.
55. Morrison JF, Walsh CT. The behavior and significance of slowbinding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301.
56. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617-627.
57. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006; 38: 628-636.
58. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: Structure activity relationships and therapeutic implications. Amsterdam: Elsevier Science BV 1994.
59. Kotsikorou E, Oldfield E. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. J Med Chem 2003; 46: 2932-2944.
60. Marma MS, Xia Z, Stewart C, et al. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem 2007; 50: 5967-5975.
61. Simoni D, Gebbia N, Invidiata FP, et al. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytesmediated activation mechanism. J Med Chem 2008; 51: 6800-6807.
62. Ebetino FH, Bayless AV, Amburgey J, et al. Elucidation of a pharmacophore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon Relat Elements 1996; 110: 217-220.
63. van Beek ER, Lowik CW, Ebetino FH, Papapoulos SE. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 1998; 23: 437-442.
64. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994; 9: 1875-1882.
65. Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem 2002; 45: 3721-3738.
66. Szabo CM, Martin MB, Oldfield E. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J Med Chem 2002; 45: 2894-2903.
67. Sanders JM, Gomez AO, Mao J, et al. 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J Med Chem 2003; 46: 5171-5183.
68. Martin MB, Arnold W, Heath HT, 3rd, Urbina JA, Oldfield E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun 1999; 263: 754-758.
69. Hounslow AM, Carran J, Brown RJ, et al. Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs. J Med Chem 2008; 51: 4170-4178.
70. Yin F, Cao R, Goddard A, Zhang Y, Oldfield E. Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase. J Am Chem Soc 2006; 128: 3524-3525.
71. Mao J, Mukherjee S, Zhang Y, et al. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J Am Chem Soc 2006; 128: 14485-14497.
72. Cheng F, Oldfield E. Inhibition of isoprene biosynthesis pathway enzymes by phosphonates, bisphosphonates, and diphosphates. J Med Chem 2004; 47: 5149-5158.
73. Goffinet M, Thoulouzan M, Pradines A, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6: 60.
74. Szabo CM, Matsumura Y, Fukura S, et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 2002; 45: 2185-2196.
75. Chen KMC, Hudock MP, Zhang Y, et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem 2008; 51: 5594-5607.
76. Zhang Y, Cao R, Yin F, et al. Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc 2009; 131: 5153-5162.
77. Cao R, Chen CK, Guo RT, Wang AH, Oldfield E. Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins 2008; 73: 431-439.
78. Artz JD, Dunford JE, Arrowood MJ, et al. Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. Chem Biol 2008; 15: 1296-1306.
79. Ling Y, Li ZH, Miranda K, Oldfield E, Moreno SN. The farnesyldiphosphate/ geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J Biol Chem 2007; 282: 30804-30816.
80. Fournier PG, Daubine F, Lundy MW, et al. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res 2008; 68: 8945-89453.
81. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001; 44: 909-916.
82. Martin MB, Sanders JM, Kendrick H, et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem 2002; 45: 2904-2914.
83. Ling Y, Sahota G, Odeh S, et al. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. J Med Chem 2005; 48: 3130-3140.
84. Ghosh S, Chan JM, Lea CR, et al. Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem 2004; 47: 175-187.
85. Garzoni LR, Waghabi MC, Baptista MM, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004; 23: 286-290.
86. Mao J, Gao YG, Odeh S, et al. Crystallization and preliminary Xray diffraction study of the farnesyl diphosphate synthase from Trypanosoma brucei. Acta Crystallogr D Biol Crystallogr 2004; 60: 1863-1866.
87. Montalvetti A, Bailey BN, Martin MB, et al. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001; 276: 33930-33937.
88. Mukkamala D, No JH, Cass LM, Chang TK, Oldfield E. Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. J Med Chem 2008; 51: 7827-7833.
89. Sanz-Rodriguez CE, Concepcion JL, Pekerar S, Oldfield E, Urbina JA. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem 2007; 282: 12377-12387.
90. Hudock MP, Sanz-Rodriguez CE, Song Y, et al. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 2006; 49: 215-223.
91. Kotsikorou E, Sahota G, Oldfield E. Bisphosphonate inhibition of phosphoglycerate kinase: quantitative structure-activity relationship and pharmacophore modeling investigation. J Med Chem 2006; 49: 6692-6703.
92. Kotsikorou E, Song Y, Chan JM, et al. Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase. J Med Chem 2005; 48: 6128-6139.
93. Szabo CM, Oldfield E. An investigation of bisphosphonate inhibition of a vacuolar proton-pumping pyrophosphatase. Biochem Biophys Res Commun 2001; 287: 468-473.
94. Yajima S, Hara K, Sanders JM, et al. Crystallographic structures of two bisphosphonate: 1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc 2004; 126: 10824-10845.
95. Holen I, Coleman RE. Bisphosphonates as Treatment of Bone Metastases. Curr Pharm Des 2010; 15(11): 1262-1271.
96. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9(32): 2643-2658.
97. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8(21): 1929-1944.